Ex­clu­sive: Prison and multi­bil­lion dol­lar buy­outs lat­er, Sam Wak­sal is all in on the biotech game, with some big-name back­ers

Sam Wak­sal isn’t let­ting a five-year prison stretch for one of the most in­fa­mous in­sid­er trad­ing scan­dals in Wall Street his­to­ry stop him from do­ing some­thing he’s good at: steer­ing ex­per­i­men­tal drugs through the clin­ic, and point­ing them to the mar­ket with block­buster val­u­a­tions that earn multi­bil­lion-dol­lar M&A deals.

Hours af­ter Sanofi put out word that it is pay­ing close to $2 bil­lion for his biotech brain­child Kad­mon, Wak­sal spelled out his lat­est plans in a rare in­ter­view with End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER